反応式
Cl.C[O:3][C:4](=[O:16])[C@H:5]([CH2:7][C:8]1[CH:13]=[CH:12][C:11]([Cl:14])=[C:10]([Br:15])[CH:9]=1)[NH2:6].[Cl:17][C:18]1[C:26]([Cl:27])=[CH:25][C:21]([C:22](O)=[O:23])=[C:20]([NH:28][S:29]([C:32]2[C:33]3[N:34]=[CH:35][CH:36]=[N:37][C:38]=3[CH:39]=[CH:40][CH:41]=2)(=[O:31])=[O:30])[CH:19]=1.N1C2C=CC=C(S(Cl)(=O)=O)C=2N=CC=1>>[Br:15][C:10]1[CH:9]=[C:8]([CH2:7][C@H:5]([NH:6][C:22](=[O:23])[C:21]2[CH:25]=[C:26]([Cl:27])[C:18]([Cl:17])=[CH:19][C:20]=2[NH:28][S:29]([C:32]2[C:33]3[N:34]=[CH:35][CH:36]=[N:37][C:38]=3[CH:39]=[CH:40][CH:41]=2)(=[O:31])=[O:30])[C:4]([OH:3])=[O:16])[CH:13]=[CH:12][C:11]=1[Cl:14]参加物
反応物 3
生成物 1
実験手順
(S)-3-(3-Bromo-4-chloro-phenyl)-2-[4,5-dichloro-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-propionic acid was prepared from 3-bromo-4-chloro-L-phenylalanine methyl ester hydrochloride and 4,5-dichloro-2-(quinoxaline-5-sulfonylamino)-benzoic acid (prepared from quinoxaline-5-sulfonyl chloride as in EXAMPLE 14, Part A) as in Example 1, Part C. Hydrolysis of the methyl ester as in EXAMPLE 2, Part E, provided the title compound. HPLC: RT=10.21 min. MS (ESI−): mass calcd. for C24H16BrCl3N4O5S, 658.74; m/z found, 655/657/659 [M−H]−. 1H NMR (400 MHz, CDCl3): 10.83 (s, 1H), 8.98 (d, J=1.8, 1H), 8.92 (d, J=1.7, 1H), 8.52 (dd, J=7.3, 1.2, 1H), 8.30 (dd, J=8.5, 1.3, 1H), 7.88 (d, J=7.5, 1H), 7.85 (s, 1H), 7.43-7.42 (m, 1H), 7.37-7.34 (m, 1H), 7.07-7.02 (m, 1H), 6.47 (d, J=7.6, 1H), 4.91-4.85 (m, 1H), 3.24-3.09 (m, 2H).
出典と根拠
- ORDレコード
- ord-c09887ff5f3143fb887186c16acefdcd
- 出典データセット
- uspto-grants-2007_11
- 特許番号
- US07297816B2
関連ノート
読み込み中…